Inducing humoral immune responses against regulatory T cells by Foxp3-Fc(IgG) fusion protein
dc.contributor.author | Niri, NM | |
dc.contributor.author | Hadjati, J | |
dc.contributor.author | Sadat, M | |
dc.contributor.author | Memarnejadian, A | |
dc.contributor.author | Aghasadeghi, M | |
dc.contributor.author | Akbarzadeh, A | |
dc.contributor.author | Zarghami, N | |
dc.date.accessioned | 2018-08-26T08:58:15Z | |
dc.date.available | 2018-08-26T08:58:15Z | |
dc.date.issued | 2015 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54670 | |
dc.description.abstract | The existence of a developed network of suppressory factors and cells against an immune response in different cancers has been proven; regulatory T cells are a typical issue. Therefore their depletion, elimination, or suppression has been assessed in different research studies that were not entirely successful. By applying an improved vaccine against regulatory T cells, we have evaluated the B cell response elicited by the vaccine in an experimental design. A previously described DNA vaccine and recombinant protein of Foxp3-Fc fusion were produced and used in the vaccination regimen. DNA construct and respective protein were injected into C57BL/6 mice. After 2 weeks, serum levels of IgG antibody and its subtypes against Foxp3 were investigated by ELISA. To produce recombinant Foxp3 for ELISA antigen coating, pET24a-Foxp3 vector was transformed into Escherichia coli strain BL21 as host cells. Afterward, protein was expressed and then purified using Ni-NTA agarose. SDS-PAGE and Western blot analysis were carried out to confirm protein expression. The expression analysis of Foxp3 was confirmed by SDS-PAGE followed by Western blot analysis. FOXP3-Fc DNA vaccine/fusion protein vaccination regimen could induce T helper-dependent humoral responses. Due to the effectiveness of Foxp3-Fc(IgG) in inducing humoral responses, it would be expected to be useful in developing vaccines in tumor therapies for the removal of regulatory T cells as a strategy for increasing the efficiency of other means of immunotherapy. é Mary Ann Liebert, Inc. 2015. | |
dc.language.iso | English | |
dc.relation.ispartof | Monoclonal Antibodies in Immunodiagnosis and Immunotherapy | |
dc.subject | DNA vaccine | |
dc.subject | Fc receptor | |
dc.subject | immunoglobulin Fc fragment | |
dc.subject | immunoglobulin G antibody | |
dc.subject | nitrilotriacetate nickel | |
dc.subject | recombinant protein | |
dc.subject | transcription factor FOXP3 | |
dc.subject | transcription factor FOXP3 immunoglobulin G1 Fc fragment fusion protein | |
dc.subject | unclassified drug | |
dc.subject | cancer vaccine | |
dc.subject | DNA vaccine | |
dc.subject | forkhead transcription factor | |
dc.subject | Foxp3 protein, mouse | |
dc.subject | hybrid protein | |
dc.subject | immunoglobulin Fc fragment | |
dc.subject | immunoglobulin G | |
dc.subject | affinity chromatography | |
dc.subject | animal experiment | |
dc.subject | antibody blood level | |
dc.subject | Article | |
dc.subject | B lymphocyte | |
dc.subject | bacterial strain | |
dc.subject | controlled study | |
dc.subject | enzyme linked immunosorbent assay | |
dc.subject | Escherichia coli | |
dc.subject | female | |
dc.subject | host cell | |
dc.subject | humoral immunity | |
dc.subject | mouse | |
dc.subject | nonhuman | |
dc.subject | polyacrylamide gel electrophoresis | |
dc.subject | priority journal | |
dc.subject | protein expression | |
dc.subject | regulatory T lymphocyte | |
dc.subject | vaccination | |
dc.subject | Western blotting | |
dc.subject | administration and dosage | |
dc.subject | animal | |
dc.subject | biosynthesis | |
dc.subject | C57BL mouse | |
dc.subject | chemistry | |
dc.subject | cytology | |
dc.subject | drug effects | |
dc.subject | gene expression | |
dc.subject | genetics | |
dc.subject | helper cell | |
dc.subject | humoral immunity | |
dc.subject | immunology | |
dc.subject | lymphocyte depletion | |
dc.subject | metabolism | |
dc.subject | molecular cloning | |
dc.subject | plasmid | |
dc.subject | regulatory T lymphocyte | |
dc.subject | vaccination | |
dc.subject | Animals | |
dc.subject | B-Lymphocytes | |
dc.subject | Cancer Vaccines | |
dc.subject | Cloning, Molecular | |
dc.subject | Escherichia coli | |
dc.subject | Female | |
dc.subject | Forkhead Transcription Factors | |
dc.subject | Gene Expression | |
dc.subject | Immunity, Humoral | |
dc.subject | Immunoglobulin Fc Fragments | |
dc.subject | Immunoglobulin G | |
dc.subject | Lymphocyte Depletion | |
dc.subject | Mice | |
dc.subject | Mice, Inbred C57BL | |
dc.subject | Plasmids | |
dc.subject | Recombinant Fusion Proteins | |
dc.subject | T-Lymphocytes, Helper-Inducer | |
dc.subject | T-Lymphocytes, Regulatory | |
dc.subject | Vaccination | |
dc.subject | Vaccines, DNA | |
dc.title | Inducing humoral immune responses against regulatory T cells by Foxp3-Fc(IgG) fusion protein | |
dc.type | Article | |
dc.citation.volume | 34 | |
dc.citation.issue | 6 | |
dc.citation.spage | 381 | |
dc.citation.epage | 385 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1089/mab.2015.0048 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |